查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493355

美國流式細胞技術市場規模、佔有率、趨勢分析報告：2024-2030 年按產品、技術、應用、最終用途、地區和細分市場進行的預測

U.S. Flow Cytometry Market Size, Share & Trends Analysis Report By Product (Software, Accessories), By Technology (Cell-based, Bead-based), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10個工作天內

價格

美國流式細胞技術市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，美國流式細胞技術市場規模將達到26.1億美元，2024年至2030年複合年成長率為6.8%。

由於癌症患者和其他慢性病患者的增加，流式細胞技術市場在美國正在迅速擴大。根據美國癌症協會（ACS）統計，2019年美國15歲至39歲的青少年和年輕人約有9,270人因癌症死亡，2020年新增癌症病例約89,500人。預計這些因素將推動市場成長。

COVID-19 大流行對市場產生了積極影響。例如，2020 年 8 月發表在 Springer 上的一項研究發現，週邊血單核細胞 (PBMC) 表現型的流式細胞技術分析呈現抗原和更有效的適應性免疫反應與 COVID-19 的康復有關。由 COVID-19 爆發導致的感染疾病和慢性病的發病率不斷增加，增加了對研究和診斷技術的需求，從而支持了市場的成長。

此外，美國擁有強大的醫療基礎設施、大量的醫療支出以及先進的流式細胞技術技術的廣泛使用。此外，隨著研究型大學從事廣泛的研究活動和製藥公司的發展，對用於研究目的的流式細胞技術工作流程的需求非常大。這得歸功於美國在醫療保健方面的大量投資、高度發展的醫療基礎設施以及尖端流式細胞技術技術的廣泛使用。

美國流式細胞技術市場報告亮點

  • 以產品來看，設備佔據市場主導地位，2023年佔35.08%。流式細胞技術儀設備在臨床診斷應用中至關重要，例如監測愛滋病毒/愛滋病的進展、檢測白血病的微量殘存疾病以及評估免疫細胞功能，這將推動該領域的發展。
  • 就技術而言，2023 年的市場佔有率將由基於電池的細分市場主導。該技術根據細胞的大小、複雜性和特定分子的存在等特徵來分析細胞。同時，以微珠為基礎的細分市場預計在預測期內將以最快的複合年成長率成長。
  • 從應用來看，2023年臨床細分市場佔據最大市場佔有率。預計工業領域在預測期內將出現最快的成長。
  • 以最終用途分類，學術機構細分市場在 2023 年佔據最大市場佔有率。臨床測試實驗室預計在預測期內成長最快。
  • 美國癌症和愛滋病毒等疾病的發生率急劇上升，推動了對美國流式細胞技術市場的需求。
  • 2024年1月，SONY生物技術發布了高度通用的流式細胞技術分析儀EC800。這種創新設備相容於多種應用，包括粒徑測定、免疫表現型分析、細胞活力、絕對細胞計數和細胞凋亡檢測。 EC800 為各種研究和診斷需求提供了經濟高效的解決方案。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國流式細胞技術市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國流式細胞技術市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國流式細胞技術市場：產品估算與趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 按產品分類的美國流式細胞技術市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 裝置
  • 試劑/耗材
  • 軟體
  • 配件
  • 服務

第5章美國流式細胞技術市場：技術評估與趨勢分析

  • 2023年及2030年技術市場佔有率
  • 細分儀表板
  • 按技術前景分類的美國流式細胞技術市場
  • 2018-2030年市場規模、預測及趨勢分析
  • 細胞基礎
  • 以微珠為基礎

第6章美國流式細胞技術市場：應用預估及趨勢分析

  • 2023年及2030年應用市場佔有率
  • 細分儀表板
  • 美國流式細胞技術市場：按應用分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 研究
  • 產業
  • 臨床

第7章美國流式細胞技術市場：最終用途估計和趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的美國流式細胞技術市場前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 臨床檢測實驗室
  • 學術機構
  • 商業組織
  • 醫院

第8章美國流式細胞技術市場：區域估計和趨勢分析

  • 2023 年和 2030 年按地區分類的市場佔有率佔有率
  • 美國流式細胞技術市場按地區展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 西
  • 中西部
  • 東北
  • 西南
  • 東南

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Sysmex Corp
    • Becton, Dickinson, and Company（BD）
    • Danaher Corp
    • Thermo Fisher Scientific, Inc.
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • Sony Biotechnology, Inc.
    • Beckman Coulter, Inc.
    • Cytek Biosciences
    • BioLegend, Inc.
    • Enzo Biochem Inc.
    • Cell Signaling Technology, Inc.
    • NeoGenomics Laboratories
    • Q2 Solutions（IQVIA）
    • Elabscience Biotechnology Inc.
    • Stratedigm, Inc.
    • BioLegend, Inc.
    • Union Biometrica, Inc.
    • BennuBio Inc.
    • ORLFO Technologies
Product Code: GVR-4-68040-286-6

U.S. Flow Cytometry Market Growth & Trends:

The U.S. flow cytometry market size is anticipated to reach USD 2.61 billion by 2030 and is growing at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for flow cytometry is expanding faster in the U.S. owing to increased cancer cases and other chronic illnesses. According to the American Cancer Society (ACS), there were roughly 9,270 cancer deaths among adolescents and young adults in the U.S. in 2019 who were between the ages of 15 and 39, and there were about 89,500 new cases of cancer diagnosed in 2020. These factors would drive market growth.

The COVID-19 pandemic had a positive effect on the market. For instance, in August 2020, research published in Springer discovered that flow cytometry analysis of peripheral blood mononuclear cell (PBMC) phenotype helped to predict the risk of COVID-19 clinical progression and indicated that improved antigen presentation and more effective adaptive immune responses are associated with recovery from COVID-19. The increasing frequency of infectious and chronic disorders, most notably the COVID-19 outbreak, has increased the need for technology for study and diagnosis, supporting the market's growth.

Furthermore, the U.S. has a robust healthcare infrastructure, significant healthcare spending, and widespread usage of highly advanced flow cytometry technologies. In addition, owing to research universities engaging in a wide range of research activities and having developed pharmaceutical enterprises, there is an enormous need for flow cytometry workflow for research purposes. This results from the U.S.'s substantial investment in healthcare, highly developed healthcare infrastructure, and widespread usage of cutting-edge flow cytometry technology.

U.S. Flow Cytometry Market Report Highlights:

  • Based on product, instrument dominated the market and accounted for 35.08% in 2023. Flow cytometry instruments are crucial in clinical diagnostics for applications such as immunophenotyping cells to monitor HIV/AIDS progression, detect minimal residual disease in leukemia, and assess immune cell function, which will fuel the segment growth
  • In terms of technology, the cell-based segment dominated the market share in 2023. This technology involves analyzing cells based on their characteristics, such as size, complexity, and the presence of specific molecules. On the other hand, the bead-based segment is expected to grow at the fastest CAGR over the forecast period
  • Based on application, the clinical segment held the largest market share in 2023. The industrial segment is expected to grow fastest over the forecast period
  • In terms of end-use, the academic institute segment held the largest market share in 2023. Clinical testing labsare anticipated to witness the fastest growth over the forecast period
  • The U.S. is the major dominating country in the market due to the surging incidence rate of diseases such as cancer and HIV amongst the population in this country, which is boosting the demand for U.S. flow cytometry market
  • In January 2024, Sony Biotechnology launched the EC800, a highly versatile flow cytometry analyzer. This innovative device caters to various applications, such as particle sizing, immunophenotyping, cell viability, absolute cell counting, and apoptosis detection, among others. The EC800 offers cost-effective solutions suitable for diverse research and diagnostic needs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. End-use
    • 1.2.5. Region
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Technology Outlook
    • 2.2.3. Application Outlook
    • 2.2.4. End-use Outlook
    • 2.2.5. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Flow Cytometry Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Flow Cytometry Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Flow Cytometry Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Flow Cytometry Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Instruments
      • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.2. Cell Analyzers
      • 4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.3. Cell Sorters
      • 4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Reagents & Consumables
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Software
      • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4. Accessories
      • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.5. Services
      • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. U.S. Flow Cytometry Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Flow Cytometry Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Cell-based
      • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Bead-based
      • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. U.S. Flow Cytometry Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Flow Cytometry Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Research
      • 6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
      • 6.4.1.2. Pharmaceutical
      • 6.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.2.2. Drug Discovery
      • 6.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.2.3. In Vitro Toxicity
      • 6.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.2.4. Stem Cell
      • 6.4.1.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.3. Apoptosis
      • 6.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.4. Cell Sorting
      • 6.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.5. Cell Cycle Analysis
      • 6.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.6. Immunology
      • 6.4.1.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.1.7. Cell Viability
      • 6.4.1.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.2. Industrial
      • 6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.4.3. Clinical
      • 6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.2. Cancer
      • 6.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.3. Organ Transplantation
      • 6.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.4. Immunodeficiency
      • 6.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.5. Hematology
      • 6.4.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 6.4.3.6. Autoimmune Disorders
      • 6.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Flow Cytometry Market: End-use Estimates & Trend Analysis

  • 7.1. End-use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Flow Cytometry Market by End-use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.4.1. Clinical Testing Labs
      • 7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Academic Institutes
      • 7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Commercial Organizations
      • 7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 7.4.3.2. Biotechnology Companies
      • 7.4.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 7.4.3.3. Pharmaceutical Companies
      • 7.4.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 7.4.3.4. CROs
      • 7.4.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Hospitals
      • 7.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. U.S. Flow Cytometry Market: Region Estimates & Trend Analysis

  • 8.1. Regional Market Share, 2023 & 2030
  • 8.2. U.S. Flow Cytometry Market by Regional Outlook
  • 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 8.3.1. West
      • 8.3.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
    • 8.3.2. Midwest
      • 8.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.3. Northeast
      • 8.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.4. Southwest
      • 8.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 8.3.5. Southeast
      • 8.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company heat map analysis, 2023
  • 9.4. Company Profiles
    • 9.4.1. Sysmex Corp
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Becton, Dickinson, and Company (B.D.)
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Danaher Corp
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Thermo Fisher Scientific, Inc.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Agilent Technologies, Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Bio-Rad Laboratories, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Sony Biotechnology, Inc.
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Beckman Coulter, Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Cytek Biosciences
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. BioLegend, Inc.
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. Enzo Biochem Inc.
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. Cell Signaling Technology, Inc.
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. NeoGenomics Laboratories
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. Q2 Solutions (IQVIA)
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Elabscience Biotechnology Inc.
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. Stratedigm, Inc.
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives
    • 9.4.17. BioLegend, Inc.
      • 9.4.17.1. Company overview
      • 9.4.17.2. Financial performance
      • 9.4.17.3. Product benchmarking
      • 9.4.17.4. Strategic initiatives
    • 9.4.18. Union Biometrica, Inc.
      • 9.4.18.1. Company overview
      • 9.4.18.2. Financial performance
      • 9.4.18.3. Product benchmarking
      • 9.4.18.4. Strategic initiatives
    • 9.4.19. BennuBio Inc.
      • 9.4.19.1. Company overview
      • 9.4.19.2. Financial performance
      • 9.4.19.3. Product benchmarking
      • 9.4.19.4. Strategic initiatives
    • 9.4.20. ORLFO Technologies
      • 9.4.20.1. Company overview
      • 9.4.20.2. Financial performance
      • 9.4.20.3. Product benchmarking
      • 9.4.20.4. Strategic initiativesw

List of Tables

  • Table 1 List of abbreviations
  • Table 2 List of secondary sources
  • Table 3 U.S. flow cytometry market by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. flow cytometry market by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S. flow cytometry market by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. flow cytometry market by end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. flow cytometry market by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. flow cytometry market: market outlook
  • Fig. 9 U.S. flow cytometry competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. flow cytometry market driver impact
  • Fig. 15 U.S. flow cytometry market restraint impact
  • Fig. 16 U.S. flow cytometry market strategic initiatives analysis
  • Fig. 17 U.S. flow cytometry market: Product movement analysis
  • Fig. 18 U.S. flow cytometry market: Product outlook and key takeaways
  • Fig. 19 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Cell analyzers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Cell sorters market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents & consumables estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Software market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Accessories estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. flow cytometry market: Technology movement analysis
  • Fig. 27 U.S. flow cytometry market: Technology outlook and key takeaways
  • Fig. 28 Cell-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Bead-based market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. flow cytometry market: Application movement analysis
  • Fig. 31 U.S. flow cytometry market: Application outlook and key takeaways
  • Fig. 32 Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Drug discovery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 In vitro toxicity market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Stem cell market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Apoptosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Cell sorting market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Cell cycle analysis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Cell viability market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Industrial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Organ transplantation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Immunodeficiency market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Hematology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Autoimmune disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. flow cytometry market: End-use movement analysis
  • Fig. 50 U.S. flow cytometry market: End-use outlook and key takeaways
  • Fig. 51 Clinical testing labs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Commercial organizations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 CROs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 U.S. flow cytometry market: Regional movement analysis
  • Fig. 59 U.S. flow cytometry market: Regional outlook and key takeaways
  • Fig. 60 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)